vasopressin variceal
Selected indexed studies
- Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis. (J Gastrointestin Liver Dis, 2021) [PMID:33723542]
- Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis. (Hepatol Int, 2015) [PMID:25788386]
- Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding. (Hepatol Int, 2023) [PMID:36542261]
_Worker-drafted node — pending editorial review._
Connections
vasopressin variceal is a side effect of
Sources
- Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis. (2021) pubmed
- Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis. (2015) pubmed
- Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding. (2023) pubmed
- A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. (1995) pubmed
- Portal hypertension. (1990) pubmed
- Medical management of variceal hemorrhage. (2010) pubmed
- Peptide-based therapy in portal hypertension. (2020) pubmed
- Esophageal varices. (1994) pubmed
- The use of vasopressin in the treatment of upper gastrointestinal haemorrhage. (1990) pubmed
- Acute variceal bleeding: risk stratification and management (including TIPS). (2018) pubmed